Neurocrine Biosciences, Inc. (NBIX)

131,64 -0,90 (-0,68 %) À partir de 12:28PM EDT. Marché ouvert.

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600
https://www.neurocrine.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 1 400

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Kevin C. Gorman Ph.D.	CEO & Director	2,05M	S.O.	1958
Mr. Matthew C. Abernethy	Chief Financial Officer	1,06M	S.O.	1980
Mr. Kyle W. Gano Ph.D.	Chief Business Development & Strategy Officer	990,12k	S.O.	1973
Dr. Eiry Wyn Roberts M.D.	Chief Medical Officer	1,12M	4,15M	1965
Ms. Julie S. Cooke	Chief Human Resources Officer	S.O.	S.O.	1966
Mr. Eric S. Benevich	Chief Commercial Officer	805k	295,52k	1965
Mr. David Warren Boyer	Chief Corporate Affairs Officer	S.O.	S.O.	1980
Dr. Ingrid Delaet Ph.D.	Chief Regulatory Officer	S.O.	S.O.	1967
Dr. Christopher F. O'Brien	Exclusive Consultant	819,37k	11,49M	1957

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Neurocrine Biosciences, Inc. en date du 1 avril 2024 est 2. Les scores principaux sont Audit : 2; Société : 1; Droits des actionnaires : 3; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.